Trial reportDiabetes care2009
A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women.
Trial report in Diabetes care, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Candidate loci shared among periodontal disease, diabetes and bone density.Frontiers in endocrinology · 2022Pooled it
- Pooled it
- Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis.Diabetes care · 2013Pooled it
- Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.Age and ageing · 2026Trial
- Daily low-dose aspirin and incident type 2 diabetes in community-dwelling healthy older adults: a post-hoc analysis of efficacy and safety in the ASPREE randomised placebo-controlled trial.The lancet. Diabetes & endocrinology · 2024Trial
- Effects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial.Diabetes, obesity & metabolism · 2019Trial
- Aspirin reduces the risk of type 2 diabetes associated with COVID-19.npj metabolic health and disease · 2025Article
- Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role ofWorld journal of psychiatry · 2024Review
- Contributions of elevated CRP, hyperglycaemia, and type 2 diabetes to cardiovascular risk in the general population: observational and Mendelian randomization studies.Cardiovascular diabetology · 2024Observational
- Self-reported oral health is associated with systemic health outcomes and all-cause mortality.Journal of the American Dental Association (1939) · 2024Article
- Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study.JAMA network open · 2020Article
- Differential expression of glycoprotein IV on monocyte subsets following high-fat diet feeding and the impact of short-term low-dose aspirin treatment.Metabolism open · 2020Article
- Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes.Molecules (Basel, Switzerland) · 2020Review
- Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Colchicine to decrease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation.Medical hypotheses · 2016Article
- Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics Study.Journal of the American Heart Association · 2015Article
- Type 2 diabetes mellitus and risk of incident atrial fibrillation in women.Journal of the American College of Cardiology · 2012Article
- Aspirin in the primary prevention of cardiovascular disease in the Women's Health Study: effect of noncompliance.European journal of epidemiology · 2012Article
- Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study.PloS one · 2011Article
- Lipoprotein(a) and risk of type 2 diabetes.Clinical chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveSubclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have directly evaluated the efficacy of aspirin in diabetes prevention at doses acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin prevents the development of clinical diabetes among initially healthy American women. RESEARCH DESIGN AND
methodsSubjects were enrolled in the Women's Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vitamin E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 38,716 women aged > or =45 years and free of clinical diabetes were randomly assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). Documented clinical type 2 diabetes was prospectively evaluated throughout the trial.
resultsAmong women randomly assigned to receive aspirin (n = 19,326) or placebo (n = 19,390), there was no statistically significant difference in the incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91-1.11]). Stratification by diabetes risk factors including age, BMI, family history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not support a modulating effect of these variables. Analyses accounting for treatment duration and adherence similarly found no beneficial effects.
conclusionsThese data suggest that long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.